ImmunoGen has struck a $440 million antibody-drug conjugate licensing deal with Takeda, moving it a step closer to recovering from the body blow of last year's Phase III flop. The heavily backloaded deal was cheered by investors.
Calico, the Google-backed biotech with ambitions to decode the aging process, has aligned itself with California's QB3, a Bay Area brain trust, to further flesh out its R&D mission.
Sun Pharmaceuticals and Ranbaxy Laboratories have jumped the final hurdle in their merger with government approval of a sale of 7 of their branded drugs to fellow India drugmaker Emcure Pharmaceuticals.
Startup MHB Labs announced the receipt of $1.1 million in seed financing from Romulus Capital and other angel investors in support of its drug delivery technology for convenient administration of a commercially available but little-used medication that could have applications in the men's health space.
GlaxoSmithKline has reached out to the storied Cold Spring Harbor Laboratory to collaborate on a potential treatment for Type 2 diabetes and obesity, inking a multiyear R&D deal.
ZAI Lab of Shanghai has in-licensed from Bristol-Myers Squibb China rights to the Phase III liver cancer drug brivanib, an oral kinase inhibitor for oncology indications including hepatocellular carcinoma.
Japan's Astellas Pharma has filed with Japan's Pharmaceutical and Medical Devices Agency for approval of PCSK9 inhibitor evolocumab for high cholesterol under the Amgen Astellas BioPharma joint venture.
Japan's Meiji Seika Pharma has terminated a license deal with U.S.-based Amalyte Pharmaceuticals for its investigational antiallergic drug ME3301 and discontinued development.
In a second major bet on Asian R&D, Eli Lilly has signed a $456 million partnership with China's Innovent Biologics to collaborate in oncology, mixing and matching assets with hopes of finding success in each company's home country.
Eli Lilly & Co. and China's Innovent Biologics agreed to co-develop at least three experimental cancer drugs--including one from Lilly's research labs and two from Innovent--in a deal that will see the Indianapolis-based company pay $56 million upfront.